Expertise in
15
conditions

Dr. Zanetta S. Lamar

Internal Medicine
Florida Cancer Specialists & Research Institute LLC
1100 Goodlette-Frank Rd N, 
Naples, FL 
Accepting New Patients
Offers Telehealth
15 Years of Experience
Expertise in
15
conditions
Florida Cancer Specialists & Research Institute LLC
1100 Goodlette-Frank Rd N, 
Naples, FL 

Overview

Zanetta Lamar is a primary care provider, practicing in Internal Medicine in Naples, Florida. She has been practicing medicine for over 15 years.

Dr. Lamar is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Large-Cell Immunoblastic Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Mycosis Fungoides.

She is actively involved in clinical research, co-authoring 19 peer reviewed articles and participating in 6 clinical trials. Dr. Lamar is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in FL

Hospital Affiliations

Lee Memorial Hospital
Naples Community Hospital
Physicians Regional Medical Center - Pine Ridge

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

Florida Cancer Specialists & Research Institute LLC
1100 Goodlette-Frank Rd N, Naples, FL 34102

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
A Randomized Phase II Pilot of Tailored Prednisone Reduction Versus Usual Care for the Treatment of Hyperglycemia During R-CHOP Chemotherapy
A Randomized Phase II Pilot of Tailored Prednisone Reduction Versus Usual Care for the Treatment of Hyperglycemia During R-CHOP Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
Study Phase: Phase 2
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2026
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustine Hydrochloride, Bortezomib, Lenalidomide
Study Phase: Phase 2
Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Classic Hodgkin Lymphoma
Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Classic Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: February 13, 2024
Intervention Type: Drug
Study Drugs: 6, 8-Bis(Benzylthio)octanoic Acid, Bendamustine
Study Phase: Phase 1
View 3 Less Clinical Trials

19 Total Publications

Cardiovascular Assessment Tool for Breast Cancer Survivors and Oncology Providers: Usability Study.
Cardiovascular Assessment Tool for Breast Cancer Survivors and Oncology Providers: Usability Study.
Journal: JMIR cancer
Published: April 09, 2020
Similar Doctors
Expertise in
112
conditions
Dr. Pavan K. Anand
Internal Medicine
Expertise in
112
conditions
Dr. Pavan K. Anand
Internal Medicine
Before you request

Pavan K Anand MD PA

599 Tamiami Trl N Ste 210, 
Naples, FL 
 (0.1 miles away)
239-435-1999
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Pavan Anand is a primary care provider, practicing in Internal Medicine in Naples, Florida. Dr. Anand is highly rated in 112 conditions, according to our data. His clinical expertise encompasses Mitochondrial Complex V Deficiency, Cytochrome C Oxidase Deficiency, High Cholesterol, and Abdominal Obesity Metabolic Syndrome. Dr. Anand is currently accepting new patients.

Expertise in
22
conditions
Dr. Brett E. Stanaland
Internal Medicine
Expertise in
22
conditions
Dr. Brett E. Stanaland
Internal Medicine

Brett E. Stanaland M.D. P.A.

1000 Goodlette Rd Ste 200, 
Naples, FL 
 (0.1 miles away)
239-434-6200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brett Stanaland is a primary care provider, practicing in Internal Medicine in Naples, Florida. Dr. Stanaland is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Allergic Rhinitis, Empyema, Grass Allergy, and Sinusitis. Dr. Stanaland is currently accepting new patients.

Expertise in
17
conditions
Dr. David H. Lindner
Internal Medicine
Expertise in
17
conditions
Dr. David H. Lindner
Internal Medicine

Nch Medical Group Pulmonology-Medical Plaza

311 9th St N Ste 304, 
Naples, FL 
 (0.1 miles away)
239-624-8250
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Lindner is a primary care provider, practicing in Internal Medicine in Naples, Florida. Dr. Lindner is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Chronic Obstructive Pulmonary Disease (COPD), Nontuberculous Mycobacterial Lung Disease, and Advanced Bronchoscopy. Dr. Lindner is currently accepting new patients.

Frequently Asked Questions about Dr. Zanetta S. Lamar

How do I make an appointment with Dr. Zanetta S. Lamar?

You can book an appointment with Dr. Zanetta S. Lamar by calling their office at 239-434-0656. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Zanetta S. Lamar a top-rated expert for Large-Cell Immunoblastic Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Zanetta S. Lamar is classified as an Distinguished expert for Large-Cell Immunoblastic Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Zanetta S. Lamar specialize in?

While Dr. Zanetta S. Lamar is a Internal Medicine, they have specific expertise in Large-Cell Immunoblastic Lymphoma, Non-Hodgkin Lymphoma, and Diffuse Large B-Cell Lymphoma (DLBCL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Zanetta S. Lamar participate in research or clinical trials?

Yes. Dr. Zanetta S. Lamar has published 19 articles and abstracts on conditions like Large-Cell Immunoblastic Lymphoma. You can view a list of Dr. Zanetta S. Lamar's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Zanetta S. Lamar accept my insurance?

Dr. Zanetta S. Lamar accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 239-434-0656 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lamar's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 61 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile